STUDY: 2.5 mg of var (nonsuppressive dose) effects on height

[MA_ascender]

It isn’t called nandrolone derivative
Nigga you think im retarded
Go see mpmd video
Tren ≠ deca

Just said what I thought he meant also rep me nigger

 

[Deleted member 77820]

Greggy weggy is on trt not hcg or hmg

Both his using both

 

[Deleted member 77820]

Just said what I thought he meant also rep me nigger

No

 

[MA_ascender]

No

Ignore list

 

[Deleted member 77820]

Ignore list

No my bhais im joking

 

[tit]

Test with a dht derivative (if you care only about height)

Dht derivatives such as masteron are the dht molecule modified to be selective to muscle tissue making it only really useful for putting on muscle. Masteron was originally used in women due to the lack of virilizng effects.

 

[tit]

Greggy weggy is on trt not hcg or hmg

you actually believe that he's only on trt?

 

[Deleted member 77820]

Dht derivatives such as masteron are the dht molecule modified to be selective to muscle tissue making it only really useful for putting on muscle. Masteron was originally used in women due to the lack of virilizng effects.

Androgenic anabolic ratio bla bla bla read all my replies
But it still cause hairloss because it has serm effects which confirm my thesis that hairloss isn’t dht but low estrogen bla bla bla
Maybe im just insane
Insanity is subjective in my opinion
Everyone is insane in his own way
010101 »10010101010101001 »1101 » »1010-010-00-0-0-0-0-00-0-0101010010101010100-0-0-0-0´’.,;-:;-,,~

 

[Deleted member 77820]

you actually believe that he's only on trt?

Yes to maintain
His on trt anav hcg inhectable fsh and replacement dose of hgh or a secreataguogue and add sarms like cardarine sr0009
Greg is a bio hacker he knows the best effective dosages to maintain his muscle mass

 

[tit]

Androgenic anabolic ratio bla bla bla read all my replies
But it still cause hairloss because it has serm effects which confirm my thesis that hairloss isn’t dht but low estrogen bla bla bla
Maybe im just insane
Insanity is subjective in my opinion
Everyone is insane in his own way
010101 »10010101010101001 »1101 » »1010-010-00-0-0-0-0-00-0-0101010010101010100-0-0-0-0´’.,;-:;-,,~

Do you have a clear set of data which shows that masteron by itself causes hairless?

 

[Deleted member 77820]

Do you have a clear set of data which shows that masteron by itself causes hairless?

Anecdotes
Go see any youtuber masteron video it would show hairloss of you still not convinced mehh
Wait for me i might go do research found a study and shit

 

[tit]

Yes to maintain
His on trt anav hcg inhectable fsh and replacement dose of hgh or a secreataguogue and add sarms like cardarine sr0009
Greg is a bio hacker he knows the best effective dosages to maintain his muscle mass

Greg is not a biohacker, at least not a real one to any degree. He is on allot more than trt though. 100 percent on growth hormone and on allot more than '250mgs' of test.

 

[tit]

Anecdotes
Go see any youtuber masteron video it would show hairloss of you still not convinced

Masteron being taken purely on its own is really rare. Are these anecdotes taken from people who only take masteron by itself?

 

[Deleted member 77820]

Greg is not a biohacker, at least not a real one to any degree. He is on allot more than trt though. 100 percent on growth hormone and on allot more than '250mgs' of test.

Mpmd is 100 mg test prop
Leo was on 400 mg test en
Also if your into that sciense Bs
I have a note on masteron if you want here :
1] De Boer, D., De Jong, E. G., Maes, R. A. A., & Van Rossum, J. M. (1992). The methyl-5α-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. The Journal of Steroid Biochemistry and Molecular Biology, 42(3-4), 411-419. [2] Liu, Y., Lu, J., Yang, S., Zhang, Q., & Xu, Y. (2016). New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids, 108, 61-67. [3] Albertsdóttir, A. D., Van Gansbeke, W., Coppieters, G., Balgimbekova, K., Van Eenoo, P., & Polet, M. (2020). Searching for new long term urinary metabolites of metenolone and drostanolone by gas chromatography mass spectrometry with a focus on non‐hydrolysed sulfates. Drug Testing and Analysis. [4] Hussain, Z., Hussain, N., Hussain, S., & Choudhary, M. I. (2020). Seven new metabolites of drostanolone heptanoate by using Beauveria bassiana, and Macrophomina phaseolina cell suspension cultures. RSC Advances, 10(1), 451-460. [5] Borodi, G., Turza, A., & Bende, A. (2020). Exploring the Polymorphism of Drostanolone Propionate. Molecules, 25(6), 1436. [6] Ayotte, C., Goudreault, D., Cyr, D., Gauthier, J., Ayotte, P., Larochelle, C., & Poirier, D. (2006). Characterisation of chemical and pharmacological properties of new steroids related to doping of athletes. Recent advances in doping analysis, 14, 151-160. [7] BLACKBURN, C., & CHILDS, J. D. (1959, March). Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast. In Proceedings of the staff meetings. Mayo Clinic (Vol. 34, No. 5, pp. 113-126). [8] Kuiper, G. G., Carlsson, B. O., Grandien, K. A. J., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J. A. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138(3), 863-870. [9] Trams, G. (1977). Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. European Journal of Cancer (1965), 13(2), 149-153. [10] Rochefort, H., & Garcia, M. (1976). Androgen on the estrogen receptor I—Binding and in vivo nuclear translocation. Steroids, 28(4), 549-560. [11] Mückter, H., Frankus, E., & More, E. (1970). Experimental Investigations with 1-(Morpholinomethyl)-4-phthalimidopiperidindione-2, 6 and Drostanolone Propionate in Dimethylbenzanthracene-induced Tumors of Sprague-Dawley Rats. Cancer Research, 30(2), 430-438. [12] Heney, N. M. (1970). Treatment of Advanced Breast Carcinoma with Drostanolone Propionate: A Case Report. Bristol Medico-Chirurgical Journal, 85(3), 75. [13] Wolff, G., & Rieche, K. (1978). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie, 1(4), 172-174. [14] Clavel, B., Cappelaere, J. P., Guerin, J., Klein, T., Pommatau, E., & Berlie, J. (1982). Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 58(34), 1919-1923. [15] Choudhary, M. I., Siddiqui, M., Yousuf, S., Fatima, N., Ahmad, M. S., & Choudhry, H. (2017). Bio-catalytic structural transformation of anti-cancer steroid, drostanolone enanthate with Cephalosporium aphidicola and Fusarium lini, and cytotoxic potential evaluation of its metabolites against certain cancer cell lines. Frontiers in pharmacology, 8, 900. [16] Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the androgen receptor in human breast cancer. Journal of mammary gland biology and neoplasia, 3(1), 95-103. [17] Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., ... & Henshall, S. M. (2009). Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer research, 69(15), 6131-6140. [18] Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., ... & Brown, M. (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer cell, 20(1), 119-131. [19] Maggiolini, M., Donzé, O., Jeannin, E., Andò, S., & Picard, D. (1999). Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer research, 59(19), 4864-4869. [20] Handa, R. J., Pak, T. R., Kudwa, A. E., Lund, T. D., & Hinds, L. (2008). An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β, 17β-diol. Hormones and behavior, 53(5), 741-752.

 

[Deleted member 77820]

Masteron being taken purely on its own is really rare. Are these anecdotes taken from people who only take masteron by itself?

They take trt + masteron
Hairloss
Take trt + primo
No hairloss
While masteron don’t lower estrogen on bloods it just block the effects of it like nolva
And primo lower slighlt estrogen on bloods
What doest that mean ????

 

[moreplatesmoreweigh]

you actually believe that he's only on trt?

Yes he’s fucking small

 

[tit]

Androgenic anabolic ratio bla bla bla read all my replies
But it still cause hairloss because it has serm effects which confirm my thesis that hairloss isn’t dht but low estrogen bla bla bla
Maybe im just insane
Insanity is subjective in my opinion
Everyone is insane in his own way
010101 »10010101010101001 »1101 » »1010-010-00-0-0-0-0-00-0-0101010010101010100-0-0-0-0´’.,;-:;-,,~

serms do not cause meaningful hairless. No where near enough to make you start norwooding.

 

[tit]

They take trt + masteron
Hairloss
Take trt + primo
No hairloss

I mean if that's really all the evidence you can give me, you don't have a strong position.

 

[tit]

Yes he’s fucking small

Unless he is constantly getting sun burnt, his redness is clearly from gh. He's an obvious con artist, I wouldn't trust a word he says.

 

[tit]

Mpmd is 100 mg test prop
Leo was on 400 mg test en
Also if your into that sciense Bs
I have a note on masteron if you want here :
1] De Boer, D., De Jong, E. G., Maes, R. A. A., & Van Rossum, J. M. (1992). The methyl-5α-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. The Journal of Steroid Biochemistry and Molecular Biology, 42(3-4), 411-419. [2] Liu, Y., Lu, J., Yang, S., Zhang, Q., & Xu, Y. (2016). New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids, 108, 61-67. [3] Albertsdóttir, A. D., Van Gansbeke, W., Coppieters, G., Balgimbekova, K., Van Eenoo, P., & Polet, M. (2020). Searching for new long term urinary metabolites of metenolone and drostanolone by gas chromatography mass spectrometry with a focus on non‐hydrolysed sulfates. Drug Testing and Analysis. [4] Hussain, Z., Hussain, N., Hussain, S., & Choudhary, M. I. (2020). Seven new metabolites of drostanolone heptanoate by using Beauveria bassiana, and Macrophomina phaseolina cell suspension cultures. RSC Advances, 10(1), 451-460. [5] Borodi, G., Turza, A., & Bende, A. (2020). Exploring the Polymorphism of Drostanolone Propionate. Molecules, 25(6), 1436. [6] Ayotte, C., Goudreault, D., Cyr, D., Gauthier, J., Ayotte, P., Larochelle, C., & Poirier, D. (2006). Characterisation of chemical and pharmacological properties of new steroids related to doping of athletes. Recent advances in doping analysis, 14, 151-160. [7] BLACKBURN, C., & CHILDS, J. D. (1959, March). Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast. In Proceedings of the staff meetings. Mayo Clinic (Vol. 34, No. 5, pp. 113-126). [8] Kuiper, G. G., Carlsson, B. O., Grandien, K. A. J., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J. A. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138(3), 863-870. [9] Trams, G. (1977). Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. European Journal of Cancer (1965), 13(2), 149-153. [10] Rochefort, H., & Garcia, M. (1976). Androgen on the estrogen receptor I—Binding and in vivo nuclear translocation. Steroids, 28(4), 549-560. [11] Mückter, H., Frankus, E., & More, E. (1970). Experimental Investigations with 1-(Morpholinomethyl)-4-phthalimidopiperidindione-2, 6 and Drostanolone Propionate in Dimethylbenzanthracene-induced Tumors of Sprague-Dawley Rats. Cancer Research, 30(2), 430-438. [12] Heney, N. M. (1970). Treatment of Advanced Breast Carcinoma with Drostanolone Propionate: A Case Report. Bristol Medico-Chirurgical Journal, 85(3), 75. [13] Wolff, G., & Rieche, K. (1978). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie, 1(4), 172-174. [14] Clavel, B., Cappelaere, J. P., Guerin, J., Klein, T., Pommatau, E., & Berlie, J. (1982). Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 58(34), 1919-1923. [15] Choudhary, M. I., Siddiqui, M., Yousuf, S., Fatima, N., Ahmad, M. S., & Choudhry, H. (2017). Bio-catalytic structural transformation of anti-cancer steroid, drostanolone enanthate with Cephalosporium aphidicola and Fusarium lini, and cytotoxic potential evaluation of its metabolites against certain cancer cell lines. Frontiers in pharmacology, 8, 900. [16] Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the androgen receptor in human breast cancer. Journal of mammary gland biology and neoplasia, 3(1), 95-103. [17] Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., ... & Henshall, S. M. (2009). Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer research, 69(15), 6131-6140. [18] Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., ... & Brown, M. (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer cell, 20(1), 119-131. [19] Maggiolini, M., Donzé, O., Jeannin, E., Andò, S., & Picard, D. (1999). Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer research, 59(19), 4864-4869. [20] Handa, R. J., Pak, T. R., Kudwa, A. E., Lund, T. D., & Hinds, L. (2008). An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β, 17β-diol. Hormones and behavior, 53(5), 741-752.

I'm to low iq to decipher what is in that wall of text, in other words, I ain't reading allat

 

[Deleted member 77820]

I'm to low iq to decipher what is in that wall of text, in other words, I ain't reading allat

Your to high iq to accept anecdotal knowledge
But to low iq to understand scientifical knowledge then how tf do i transmit the message to you
If you have hairloss pls try it and testify it
If you get results write a thead and tagmaxx me a
If you get bad results diss me in one of your threads with pictures

 

[tit]

Your to high iq to accept anecdotal knowledge

Im willing to accept the anecdotal evidence of someone who takes masteron on its own and experiences hairless. When someone who takes a compound which causes hair loss, experiences hair loss,I'm gonna blame it on the compound which causes hair loss. What you are doing is overly speculative. Not a strong argument at all.

But to low iq to understand scientifical knowledge

Summarise what it means, I don't have a background in biology, I can't read that and understand it.

 

[tit]

Mpmd is 100 mg test prop
Leo was on 400 mg test en
Also if your into that sciense Bs
I have a note on masteron if you want here :
1] De Boer, D., De Jong, E. G., Maes, R. A. A., & Van Rossum, J. M. (1992). The methyl-5α-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. The Journal of Steroid Biochemistry and Molecular Biology, 42(3-4), 411-419. [2] Liu, Y., Lu, J., Yang, S., Zhang, Q., & Xu, Y. (2016). New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids, 108, 61-67. [3] Albertsdóttir, A. D., Van Gansbeke, W., Coppieters, G., Balgimbekova, K., Van Eenoo, P., & Polet, M. (2020). Searching for new long term urinary metabolites of metenolone and drostanolone by gas chromatography mass spectrometry with a focus on non‐hydrolysed sulfates. Drug Testing and Analysis. [4] Hussain, Z., Hussain, N., Hussain, S., & Choudhary, M. I. (2020). Seven new metabolites of drostanolone heptanoate by using Beauveria bassiana, and Macrophomina phaseolina cell suspension cultures. RSC Advances, 10(1), 451-460. [5] Borodi, G., Turza, A., & Bende, A. (2020). Exploring the Polymorphism of Drostanolone Propionate. Molecules, 25(6), 1436. [6] Ayotte, C., Goudreault, D., Cyr, D., Gauthier, J., Ayotte, P., Larochelle, C., & Poirier, D. (2006). Characterisation of chemical and pharmacological properties of new steroids related to doping of athletes. Recent advances in doping analysis, 14, 151-160. [7] BLACKBURN, C., & CHILDS, J. D. (1959, March). Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast. In Proceedings of the staff meetings. Mayo Clinic (Vol. 34, No. 5, pp. 113-126). [8] Kuiper, G. G., Carlsson, B. O., Grandien, K. A. J., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J. A. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138(3), 863-870. [9] Trams, G. (1977). Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. European Journal of Cancer (1965), 13(2), 149-153. [10] Rochefort, H., & Garcia, M. (1976). Androgen on the estrogen receptor I—Binding and in vivo nuclear translocation. Steroids, 28(4), 549-560. [11] Mückter, H., Frankus, E., & More, E. (1970). Experimental Investigations with 1-(Morpholinomethyl)-4-phthalimidopiperidindione-2, 6 and Drostanolone Propionate in Dimethylbenzanthracene-induced Tumors of Sprague-Dawley Rats. Cancer Research, 30(2), 430-438. [12] Heney, N. M. (1970). Treatment of Advanced Breast Carcinoma with Drostanolone Propionate: A Case Report. Bristol Medico-Chirurgical Journal, 85(3), 75. [13] Wolff, G., & Rieche, K. (1978). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie, 1(4), 172-174. [14] Clavel, B., Cappelaere, J. P., Guerin, J., Klein, T., Pommatau, E., & Berlie, J. (1982). Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 58(34), 1919-1923. [15] Choudhary, M. I., Siddiqui, M., Yousuf, S., Fatima, N., Ahmad, M. S., & Choudhry, H. (2017). Bio-catalytic structural transformation of anti-cancer steroid, drostanolone enanthate with Cephalosporium aphidicola and Fusarium lini, and cytotoxic potential evaluation of its metabolites against certain cancer cell lines. Frontiers in pharmacology, 8, 900. [16] Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the androgen receptor in human breast cancer. Journal of mammary gland biology and neoplasia, 3(1), 95-103. [17] Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., ... & Henshall, S. M. (2009). Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer research, 69(15), 6131-6140. [18] Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., ... & Brown, M. (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer cell, 20(1), 119-131. [19] Maggiolini, M., Donzé, O., Jeannin, E., Andò, S., & Picard, D. (1999). Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer research, 59(19), 4864-4869. [20] Handa, R. J., Pak, T. R., Kudwa, A. E., Lund, T. D., & Hinds, L. (2008). An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β, 17β-diol. Hormones and behavior, 53(5), 741-752.

Wait you fucking idiot. This is nothing. This is just a compilation of names of studies relating to masteron. How is this supposed to prove your point. Unless you can site the specific study which reinforces your point, you are just full of shit. Classic ethnic debate strategy. Just say a bunch of random shit to confuse people.

 

[tit]

Mpmd is 100 mg test prop
Leo was on 400 mg test en
Also if your into that sciense Bs
I have a note on masteron if you want here :
1] De Boer, D., De Jong, E. G., Maes, R. A. A., & Van Rossum, J. M. (1992). The methyl-5α-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites. The Journal of Steroid Biochemistry and Molecular Biology, 42(3-4), 411-419. [2] Liu, Y., Lu, J., Yang, S., Zhang, Q., & Xu, Y. (2016). New drostanolone metabolites in human urine by liquid chromatography time-of-flight tandem mass spectrometry and their application for doping control. Steroids, 108, 61-67. [3] Albertsdóttir, A. D., Van Gansbeke, W., Coppieters, G., Balgimbekova, K., Van Eenoo, P., & Polet, M. (2020). Searching for new long term urinary metabolites of metenolone and drostanolone by gas chromatography mass spectrometry with a focus on non‐hydrolysed sulfates. Drug Testing and Analysis. [4] Hussain, Z., Hussain, N., Hussain, S., & Choudhary, M. I. (2020). Seven new metabolites of drostanolone heptanoate by using Beauveria bassiana, and Macrophomina phaseolina cell suspension cultures. RSC Advances, 10(1), 451-460. [5] Borodi, G., Turza, A., & Bende, A. (2020). Exploring the Polymorphism of Drostanolone Propionate. Molecules, 25(6), 1436. [6] Ayotte, C., Goudreault, D., Cyr, D., Gauthier, J., Ayotte, P., Larochelle, C., & Poirier, D. (2006). Characterisation of chemical and pharmacological properties of new steroids related to doping of athletes. Recent advances in doping analysis, 14, 151-160. [7] BLACKBURN, C., & CHILDS, J. D. (1959, March). Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast. In Proceedings of the staff meetings. Mayo Clinic (Vol. 34, No. 5, pp. 113-126). [8] Kuiper, G. G., Carlsson, B. O., Grandien, K. A. J., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J. A. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138(3), 863-870. [9] Trams, G. (1977). Effect of drostanolone propionate on the binding of oestradiol and dihydrotestosterone by normal and malignant target tissues. European Journal of Cancer (1965), 13(2), 149-153. [10] Rochefort, H., & Garcia, M. (1976). Androgen on the estrogen receptor I—Binding and in vivo nuclear translocation. Steroids, 28(4), 549-560. [11] Mückter, H., Frankus, E., & More, E. (1970). Experimental Investigations with 1-(Morpholinomethyl)-4-phthalimidopiperidindione-2, 6 and Drostanolone Propionate in Dimethylbenzanthracene-induced Tumors of Sprague-Dawley Rats. Cancer Research, 30(2), 430-438. [12] Heney, N. M. (1970). Treatment of Advanced Breast Carcinoma with Drostanolone Propionate: A Case Report. Bristol Medico-Chirurgical Journal, 85(3), 75. [13] Wolff, G., & Rieche, K. (1978). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. Onkologie, 1(4), 172-174. [14] Clavel, B., Cappelaere, J. P., Guerin, J., Klein, T., Pommatau, E., & Berlie, J. (1982). Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 58(34), 1919-1923. [15] Choudhary, M. I., Siddiqui, M., Yousuf, S., Fatima, N., Ahmad, M. S., & Choudhry, H. (2017). Bio-catalytic structural transformation of anti-cancer steroid, drostanolone enanthate with Cephalosporium aphidicola and Fusarium lini, and cytotoxic potential evaluation of its metabolites against certain cancer cell lines. Frontiers in pharmacology, 8, 900. [16] Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998). Role of the androgen receptor in human breast cancer. Journal of mammary gland biology and neoplasia, 3(1), 95-103. [17] Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., ... & Henshall, S. M. (2009). Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer research, 69(15), 6131-6140. [18] Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., ... & Brown, M. (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer cell, 20(1), 119-131. [19] Maggiolini, M., Donzé, O., Jeannin, E., Andò, S., & Picard, D. (1999). Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer research, 59(19), 4864-4869. [20] Handa, R. J., Pak, T. R., Kudwa, A. E., Lund, T. D., & Hinds, L. (2008). An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β, 17β-diol. Hormones and behavior, 53(5), 741-752.

Hey bro looks at this 'note' I have which proves my point:
The prevalence of hypertension in the early twentieth century varied in India, ranging from 2-15% in Urban India and 2-8% in Rural India. In the inter heart and inter stroke study, hypertension accounted for 17.9% and 34.6% of population attributable risk for coronary artery disease and stroke respectively. CRP appears in serum in response to a variety of inflammatory stimuli .Raised level of hs-CRP is seen with increasing with age, during an infection, inflammation, coronary artery diseases, obesity, sepsis, smoking and vasculitis. CRP is also a factor in the development of atherosclerotic plaque. Although CRP was believed to be a marker of vascular inflammation, recent research indicates that it plays an active role in atherogenesis. So in this study we measured serum hs- CRP in patients with essential hypertension and correlated with blood pressure. The study consists of 50 patients with essential hypertension with antihypertensive medications. in the age group of 40 to 60 years of both sexes and 25 normotensive subjects with no history of cardiovascular, neoplastic, hepatic, renal, infectious or auto immune disease. IHEC clearance and informed consent were obtained. hs-CRP was measured by ELISA kit. Our study showed significantly elevated serum hs-CRP level in hypertensive subjects in comparison with control subjects. To find out the relationship between physiological and biochemical parameters with CRP Pearson correlation coefficient has been applied. The level of significance has been fixed as 5% (p<0.05). SPSS15 software has been used for calculation. Our study showed significantly elevated serum hs-CRP level in hypertensive subjects in comparison with control subjects. But there is no correlation of hs-CRP level with both systolic and diastolic pressure. Several studies have shown inflammatory markers such as CRP as an independent determinant of endothelium dependent vascular function among patient with coronary heart disease (CHD) in patients with hypertension. There was no significant correlation was observed between levels of hs-CRP and systolic and diastolic blood pressure in this study but there was a significant elevation hs-CRP level was observed in hypertensive patients.

 

[Deleted member 77820]

Hey bro looks at this 'note' I have which proves my point:
The prevalence of hypertension in the early twentieth century varied in India, ranging from 2-15% in Urban India and 2-8% in Rural India. In the inter heart and inter stroke study, hypertension accounted for 17.9% and 34.6% of population attributable risk for coronary artery disease and stroke respectively. CRP appears in serum in response to a variety of inflammatory stimuli .Raised level of hs-CRP is seen with increasing with age, during an infection, inflammation, coronary artery diseases, obesity, sepsis, smoking and vasculitis. CRP is also a factor in the development of atherosclerotic plaque. Although CRP was believed to be a marker of vascular inflammation, recent research indicates that it plays an active role in atherogenesis. So in this study we measured serum hs- CRP in patients with essential hypertension and correlated with blood pressure. The study consists of 50 patients with essential hypertension with antihypertensive medications. in the age group of 40 to 60 years of both sexes and 25 normotensive subjects with no history of cardiovascular, neoplastic, hepatic, renal, infectious or auto immune disease. IHEC clearance and informed consent were obtained. hs-CRP was measured by ELISA kit. Our study showed significantly elevated serum hs-CRP level in hypertensive subjects in comparison with control subjects. To find out the relationship between physiological and biochemical parameters with CRP Pearson correlation coefficient has been applied. The level of significance has been fixed as 5% (p<0.05). SPSS15 software has been used for calculation. Our study showed significantly elevated serum hs-CRP level in hypertensive subjects in comparison with control subjects. But there is no correlation of hs-CRP level with both systolic and diastolic pressure. Several studies have shown inflammatory markers such as CRP as an independent determinant of endothelium dependent vascular function among patient with coronary heart disease (CHD) in patients with hypertension. There was no significant correlation was observed between levels of hs-CRP and systolic and diastolic blood pressure in this study but there was a significant elevation hs-CRP level was observed in hypertensive patients.

Wtf does this have to do with anything

 

[Deleted member 77820]

Wait you fucking idiot. This is nothing. This is just a compilation of names of studies relating to masteron. How is this supposed to prove your point. Unless you can site the specific study which reinforces your point, you are just full of shit. Classic ethnic debate strategy. Just say a bunch of random shit to confuse people.

No i said if you interrested i bookmarked those studies

 

[tit]

No i said if you interrested i bookmarked those studies

No, you said if I was interested in the science, here was a note.

 

[Deleted member 77820]

No, you said if I was interested in the science, here was a note.

Forgot to mention
Read this thread
Thread 'Exposing the biggest org fraud that is @piec (balding cell gftih)'
https://looksmax.org/threads/exposing-the-biggest-org-fraud-that-is-piec-balding-cell-gftih.1195555/

 

[moreplatesmoreweigh]

Unless he is constantly getting sun burnt, his redness is clearly from gh. He's an obvious con artist, I wouldn't trust a word he says.

As 50% natty on TikTok said. TRT is Tren Recombinant growth hormone Test